25 XP   0   0   10

Pharmaron Beijing Co Ltd
Buy, Hold or Sell?

Let's analyse Pharmaron together

PenkeI guess you are interested in Pharmaron Beijing Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pharmaron Beijing Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Pharmaron Beijing Co Ltd

I send you an email if I find something interesting about Pharmaron Beijing Co Ltd.

Quick analysis of Pharmaron (30 sec.)










What can you expect buying and holding a share of Pharmaron? (30 sec.)

How much money do you get?

How much money do you get?
HK$0.03
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
HK$8.01
Expected worth in 1 year
HK$6.12
How sure are you?
88.0%

+ What do you gain per year?

Total Gains per Share
HK$-1.61
Return On Investment
-18.7%

For what price can you sell your share?

Current Price per Share
HK$8.64
Expected price per share
HK$0 - HK$8.65
How sure are you?
50%

1. Valuation of Pharmaron (5 min.)




Live pricePrice per Share (EOD)

HK$8.64

Intrinsic Value Per Share

HK$-1.60 - HK$-1.62

Total Value Per Share

HK$6.41 - HK$6.39

2. Growth of Pharmaron (5 min.)




Is Pharmaron growing?

Current yearPrevious yearGrowGrow %
How rich?$1.8b$1.4b$231.4m13.8%

How much money is Pharmaron making?

Current yearPrevious yearGrowGrow %
Making money$55.2m$47.4m$7.8m14.1%
Net Profit Margin13.9%13.3%--

How much money comes from the company's main activities?

3. Financial Health of Pharmaron (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#36 / 1011

Most Revenue
#39 / 1011

Most Profit
#44 / 1011

Most Efficient
#98 / 1011

What can you expect buying and holding a share of Pharmaron? (5 min.)

Welcome investor! Pharmaron's management wants to use your money to grow the business. In return you get a share of Pharmaron.

What can you expect buying and holding a share of Pharmaron?

First you should know what it really means to hold a share of Pharmaron. And how you can make/lose money.

Speculation

The Price per Share of Pharmaron is HK$8.64. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pharmaron.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pharmaron, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is HK$8.01. Based on the TTM, the Book Value Change Per Share is HK$-0.47 per quarter. Based on the YOY, the Book Value Change Per Share is HK$0.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is HK$0.07 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pharmaron.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 HK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per Share
Usd Eps0.040.4%0.040.5%0.040.5%0.040.4%0.030.4%
Usd Book Value Change Per Share0.101.2%-0.06-0.7%0.020.2%0.030.4%0.040.5%
Usd Dividend Per Share0.000.0%0.010.1%0.010.1%0.010.1%0.010.1%
Usd Total Gains Per Share0.111.2%-0.05-0.6%0.030.3%0.040.5%0.050.5%
Usd Price Per Share2.02-2.92-8.49-9.06-7.25-
Price to Earnings Ratio14.14-18.62-58.24-61.50-49.20-
Price-to-Total Gains Ratio18.90--211.21-578.14-256.87-256.87-
Price to Book Ratio1.97-2.75-6.99-8.26-6.61-
Price-to-Total Gains Ratio18.90--211.21-578.14-256.87-256.87-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.102464
Number of shares907
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share-0.060.03
Usd Total Gains Per Share-0.050.04
Gains per Quarter (907 shares)-46.6736.66
Gains per Year (907 shares)-186.68146.65
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
132-218-19727119137
263-437-38455239284
395-655-57182358431
4127-873-758110477578
5158-1092-945137596725
6190-1310-1132164716872
7222-1528-13191928351019
8253-1747-15062199541166
9285-1965-169324710731313
10317-2183-188027411931460

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%25.00.00.0100.0%25.00.00.0100.0%
Book Value Change Per Share2.02.00.050.0%9.03.00.075.0%16.04.00.080.0%20.04.01.080.0%20.04.01.080.0%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%25.00.00.0100.0%25.00.00.0100.0%
Total Gains per Share2.02.00.050.0%10.02.00.083.3%17.03.00.085.0%22.03.00.088.0%22.03.00.088.0%

Fundamentals of Pharmaron

About Pharmaron Beijing Co Ltd

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, rest of Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Preparation Process Development, and Production Services; Clinical Research Services; Macromolecule and Cell, and Gene Therapy Services; and Others. The company offers laboratory chemical services, including medicinal chemistry, synthetic chemistry, analytical and purification chemistry, and computer-aided drug design; bioscience services, such as in vitro and in vivo drug metabolism and pharmacokinetics, in vitro biology and in vivo pharmacology, drug safety evaluation, and US laboratory services; and process development and production, material science/preparation, preparation development and production, and analytical development services. It also provides radiolabeling science and early clinical trial services; clinical trial and clinical research site management services; and macromolecular drug discovery and development, and production services (CDMO), as well as cell and gene therapy laboratory, and gene therapy CDMO services. In addition, the company provides safety assessment, and chemistry, manufacturing, and controls services. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-04-16 21:02:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Pharmaron Beijing Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Pharmaron earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Pharmaron to the Biotechnology industry mean.
  • A Net Profit Margin of 15.5% means that $0.16 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 15.5%. The company is making a huge profit. +2
  • The TTM is 13.9%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ15.5%TTM13.9%+1.7%
TTM13.9%YOY13.3%+0.6%
TTM13.9%5Y17.0%-3.1%
5Y17.0%10Y15.8%+1.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.5%-196.1%+211.6%
TTM13.9%-211.9%+225.8%
YOY13.3%-277.7%+291.0%
5Y17.0%-432.9%+449.9%
10Y15.8%-599.3%+615.1%
1.1.2. Return on Assets

Shows how efficient Pharmaron is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pharmaron to the Biotechnology industry mean.
  • 1.7% Return on Assets means that Pharmaron generated $0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 1.7%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.7%TTM1.7%+0.0%
TTM1.7%YOY1.8%0.0%
TTM1.7%5Y2.2%-0.4%
5Y2.2%10Y2.1%+0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7%-13.3%+15.0%
TTM1.7%-12.7%+14.4%
YOY1.8%-11.8%+13.6%
5Y2.2%-14.0%+16.2%
10Y2.1%-15.9%+18.0%
1.1.3. Return on Equity

Shows how efficient Pharmaron is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pharmaron to the Biotechnology industry mean.
  • 3.7% Return on Equity means Pharmaron generated $0.04 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 3.7%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.4%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.7%TTM3.4%+0.3%
TTM3.4%YOY3.3%+0.1%
TTM3.4%5Y3.6%-0.2%
5Y3.6%10Y3.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7%-16.9%+20.6%
TTM3.4%-16.0%+19.4%
YOY3.3%-15.1%+18.4%
5Y3.6%-19.7%+23.3%
10Y3.6%-20.5%+24.1%

1.2. Operating Efficiency of Pharmaron Beijing Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Pharmaron is operating .

  • Measures how much profit Pharmaron makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pharmaron to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM8.1%-8.1%
TTM8.1%YOY15.5%-7.4%
TTM8.1%5Y18.0%-10.0%
5Y18.0%10Y17.5%+0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--290.9%+290.9%
TTM8.1%-224.4%+232.5%
YOY15.5%-288.3%+303.8%
5Y18.0%-479.5%+497.5%
10Y17.5%-625.2%+642.7%
1.2.2. Operating Ratio

Measures how efficient Pharmaron is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.49 means that the operating costs are $1.49 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 1.493. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.166. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.493TTM1.166+0.328
TTM1.166YOY0.830+0.335
TTM1.1665Y0.881+0.285
5Y0.88110Y0.874+0.007
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4933.110-1.617
TTM1.1663.266-2.100
YOY0.8303.783-2.953
5Y0.8815.657-4.776
10Y0.8747.783-6.909

1.3. Liquidity of Pharmaron Beijing Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Pharmaron is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.98 means the company has $2.98 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 2.976. The company is able to pay all its short-term debts. +1
  • The TTM is 2.106. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.976TTM2.106+0.869
TTM2.106YOY2.009+0.098
TTM2.1065Y2.649-0.543
5Y2.64910Y2.285+0.364
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9763.905-0.929
TTM2.1064.212-2.106
YOY2.0095.337-3.328
5Y2.6496.062-3.413
10Y2.2856.401-4.116
1.3.2. Quick Ratio

Measures if Pharmaron is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pharmaron to the Biotechnology industry mean.
  • A Quick Ratio of 0.78 means the company can pay off $0.78 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 0.784. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.391. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ0.784TTM1.391-0.607
TTM1.391YOY1.788-0.397
TTM1.3915Y2.497-1.106
5Y2.49710Y2.115+0.382
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7843.572-2.788
TTM1.3914.001-2.610
YOY1.7885.364-3.576
5Y2.4976.009-3.512
10Y2.1156.287-4.172

1.4. Solvency of Pharmaron Beijing Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Pharmaron assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pharmaron to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.50 means that Pharmaron assets are financed with 50.0% credit (debt) and the remaining percentage (100% - 50.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 0.500. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.471. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.500TTM0.471+0.029
TTM0.471YOY0.460+0.011
TTM0.4715Y0.382+0.089
5Y0.38210Y0.405-0.022
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5000.336+0.164
TTM0.4710.334+0.137
YOY0.4600.271+0.189
5Y0.3820.366+0.016
10Y0.4050.389+0.016
1.4.2. Debt to Equity Ratio

Measures if Pharmaron is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pharmaron to the Biotechnology industry mean.
  • A Debt to Equity ratio of 105.4% means that company has $1.05 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pharmaron Beijing Co Ltd:

  • The MRQ is 1.054. The company is able to pay all its debts with equity. +1
  • The TTM is 0.927. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.054TTM0.927+0.128
TTM0.927YOY0.866+0.060
TTM0.9275Y0.685+0.242
5Y0.68510Y0.744-0.059
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0540.382+0.672
TTM0.9270.397+0.530
YOY0.8660.341+0.525
5Y0.6850.432+0.253
10Y0.7440.465+0.279

2. Market Valuation of Pharmaron Beijing Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Pharmaron generates.

  • Above 15 is considered overpriced but always compare Pharmaron to the Biotechnology industry mean.
  • A PE ratio of 14.14 means the investor is paying $14.14 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pharmaron Beijing Co Ltd:

  • The EOD is 7.725. Based on the earnings, the company is underpriced. +1
  • The MRQ is 14.144. Based on the earnings, the company is underpriced. +1
  • The TTM is 18.624. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD7.725MRQ14.144-6.419
MRQ14.144TTM18.624-4.480
TTM18.624YOY58.235-39.612
TTM18.6245Y61.505-42.881
5Y61.50510Y49.204+12.301
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.725-2.262+9.987
MRQ14.144-2.599+16.743
TTM18.624-2.674+21.298
YOY58.235-4.133+62.368
5Y61.505-6.258+67.763
10Y49.204-6.171+55.375
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pharmaron Beijing Co Ltd:

  • The EOD is 35.924. Based on how much money comes from the company's main activities, the company is fair priced.
  • The MRQ is 65.778. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 211.167. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD35.924MRQ65.778-29.854
MRQ65.778TTM211.167-145.388
TTM211.167YOY-59.436+270.603
TTM211.1675Y-28.254+239.421
5Y-28.25410Y-22.603-5.651
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD35.924-2.913+38.837
MRQ65.778-3.275+69.053
TTM211.167-3.508+214.675
YOY-59.436-5.620-53.816
5Y-28.254-8.306-19.948
10Y-22.603-8.854-13.749
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Pharmaron is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.97 means the investor is paying $1.97 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Pharmaron Beijing Co Ltd:

  • The EOD is 1.078. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.975. Based on the equity, the company is underpriced. +1
  • The TTM is 2.750. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.078MRQ1.975-0.896
MRQ1.975TTM2.750-0.776
TTM2.750YOY6.986-4.236
TTM2.7505Y8.264-5.514
5Y8.26410Y6.611+1.653
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.0781.858-0.780
MRQ1.9752.090-0.115
TTM2.7502.091+0.659
YOY6.9862.866+4.120
5Y8.2643.488+4.776
10Y6.6113.836+2.775
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Pharmaron Beijing Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.807-0.472+158%0.129+526%0.258+213%0.320+152%
Book Value Per Share--8.0118.249-3%9.577-16%7.789+3%6.755+19%
Current Ratio--2.9762.106+41%2.009+48%2.649+12%2.285+30%
Debt To Asset Ratio--0.5000.471+6%0.460+9%0.382+31%0.405+24%
Debt To Equity Ratio--1.0540.927+14%0.866+22%0.685+54%0.744+42%
Dividend Per Share--0.0300.068-56%0.092-67%0.059-49%0.052-42%
Eps--0.2800.322-13%0.313-11%0.289-3%0.259+8%
Free Cash Flow Per Share--0.060-0.192+419%-0.321+633%-0.079+231%-0.060+200%
Free Cash Flow To Equity Per Share--0.060-0.095+258%-0.644+1170%0.263-77%0.219-73%
Gross Profit Margin--1.0000.919+9%0.830+20%0.880+14%0.867+15%
Intrinsic Value_10Y_max---1.622--------
Intrinsic Value_10Y_min---1.600--------
Intrinsic Value_1Y_max---0.618--------
Intrinsic Value_1Y_min---0.607--------
Intrinsic Value_3Y_max---1.509--------
Intrinsic Value_3Y_min---1.448--------
Intrinsic Value_5Y_max---1.982--------
Intrinsic Value_5Y_min---1.870--------
Market Cap2605279610.880-985%28266103498.92035924352811.680-21%78960094931.875-64%85598555036.230-67%68478844028.984-59%
Net Profit Margin--0.1550.139+12%0.133+17%0.170-9%0.158-2%
Operating Margin---0.081-100%0.155-100%0.180-100%0.175-100%
Operating Ratio--1.4931.166+28%0.830+80%0.881+70%0.874+71%
Pb Ratio1.078-83%1.9752.750-28%6.986-72%8.264-76%6.611-70%
Pe Ratio7.725-83%14.14418.624-24%58.235-76%61.505-77%49.204-71%
Price Per Share8.640-83%15.82022.903-31%66.575-76%70.988-78%56.790-72%
Price To Free Cash Flow Ratio35.924-83%65.778211.167-69%-59.436+190%-28.254+143%-22.603+134%
Price To Total Gains Ratio10.325-83%18.905-211.209+1217%578.140-97%256.871-93%256.871-93%
Quick Ratio--0.7841.391-44%1.788-56%2.497-69%2.115-63%
Return On Assets--0.0170.017+1%0.018-1%0.022-19%0.021-17%
Return On Equity--0.0370.034+8%0.033+11%0.036+2%0.036+1%
Total Gains Per Share--0.837-0.403+148%0.221+278%0.317+164%0.372+125%
Usd Book Value--1826504616.8421680677089.137+9%1449239928.180+26%1240701250.314+47%1051776366.014+74%
Usd Book Value Change Per Share--0.103-0.060+158%0.016+526%0.033+213%0.041+152%
Usd Book Value Per Share--1.0221.053-3%1.222-16%0.994+3%0.862+19%
Usd Dividend Per Share--0.0040.009-56%0.012-67%0.008-49%0.007-42%
Usd Eps--0.0360.041-13%0.040-11%0.037-3%0.033+8%
Usd Free Cash Flow--13707996.889-36001922.315+363%-48516840.053+454%-13578759.672+199%-10500752.253+177%
Usd Free Cash Flow Per Share--0.008-0.024+419%-0.041+633%-0.010+231%-0.008+200%
Usd Free Cash Flow To Equity Per Share--0.008-0.012+258%-0.082+1170%0.034-77%0.028-73%
Usd Market Cap332433678.348-985%3606754806.4624583947418.770-21%10075308113.307-64%10922375622.623-67%8737900498.098-59%
Usd Price Per Share1.102-83%2.0192.922-31%8.495-76%9.058-78%7.246-72%
Usd Profit--63751937.38855227359.107+15%47414869.569+34%43850187.520+45%37366938.796+71%
Usd Revenue--410850259.131397985537.007+3%354119903.332+16%263107988.508+56%230276106.516+78%
Usd Total Gains Per Share--0.107-0.051+148%0.028+278%0.040+164%0.047+125%
 EOD+4 -4MRQTTM+22 -14YOY+19 -175Y+18 -1810Y+20 -16

3.2. Fundamental Score

Let's check the fundamental score of Pharmaron Beijing Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-157.725
Price to Book Ratio (EOD)Between0-11.078
Net Profit Margin (MRQ)Greater than00.155
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.784
Current Ratio (MRQ)Greater than12.976
Debt to Asset Ratio (MRQ)Less than10.500
Debt to Equity Ratio (MRQ)Less than11.054
Return on Equity (MRQ)Greater than0.150.037
Return on Assets (MRQ)Greater than0.050.017
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Pharmaron Beijing Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.000
Ma 20Greater thanMa 509.312
Ma 50Greater thanMa 1009.844
Ma 100Greater thanMa 20012.194
OpenGreater thanClose8.390
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Selling General Administrative  320,985127,080448,065-426,90421,161503,742524,903-960,649-435,746



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets26,476,713
Total Liabilities13,238,666
Total Stockholder Equity12,556,797
 As reported
Total Liabilities 13,238,666
Total Stockholder Equity+ 12,556,797
Total Assets = 26,476,713

Assets

Total Assets26,476,713
Total Current Assets10,874,413
Long-term Assets15,602,300
Total Current Assets
Cash And Cash Equivalents 5,918,915
Short-term Investments 621,983
Net Receivables 2,242,026
Inventory 1,013,079
Other Current Assets 553,075
Total Current Assets  (as reported)10,874,413
Total Current Assets  (calculated)10,349,078
+/- 525,335
Long-term Assets
Property Plant Equipment 9,904,810
Goodwill 2,780,918
Intangible Assets 789,057
Long-term Assets Other 291,215
Long-term Assets  (as reported)15,602,300
Long-term Assets  (calculated)13,766,000
+/- 1,836,300

Liabilities & Shareholders' Equity

Total Current Liabilities3,654,476
Long-term Liabilities9,584,191
Total Stockholder Equity12,556,797
Total Current Liabilities
Short Long Term Debt 577,071
Accounts payable 412,221
Other Current Liabilities 24,586
Total Current Liabilities  (as reported)3,654,476
Total Current Liabilities  (calculated)1,013,877
+/- 2,640,598
Long-term Liabilities
Long term Debt 8,199,665
Capital Lease Obligations Min Short Term Debt585,197
Long-term Liabilities Other 117,582
Long-term Liabilities  (as reported)9,584,191
Long-term Liabilities  (calculated)8,902,445
+/- 681,746
Total Stockholder Equity
Retained Earnings 5,204,512
Total Stockholder Equity (as reported)12,556,797
Total Stockholder Equity (calculated)5,204,512
+/- 7,352,285
Other
Capital Stock1,787,394
Common Stock Shares Outstanding 1,786,732
Net Debt 2,857,821
Net Invested Capital 21,333,534
Net Working Capital 7,219,937
Property Plant and Equipment Gross 9,904,810



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-31
> Total Assets 
3,919,174
0
4,265,475
4,477,285
4,625,479
5,143,597
5,347,327
5,574,184
9,935,038
9,276,892
9,983,834
10,486,354
11,908,793
12,761,893
17,037,700
17,536,056
18,389,124
18,660,921
18,966,871
19,706,905
20,492,557
21,047,569
22,390,082
22,476,014
26,476,713
26,476,71322,476,01422,390,08221,047,56920,492,55719,706,90518,966,87118,660,92118,389,12417,536,05617,037,70012,761,89311,908,79310,486,3549,983,8349,276,8929,935,0385,574,1845,347,3275,143,5974,625,4794,477,2854,265,47503,919,174
   > Total Current Assets 
1,078,175
0
1,165,174
1,251,884
1,280,660
1,787,068
1,604,707
1,715,836
5,944,451
5,188,426
5,283,465
5,542,103
5,540,378
5,064,977
8,818,013
8,654,911
8,643,502
7,646,205
7,001,671
6,652,813
6,536,007
6,558,584
7,431,010
7,220,418
10,874,413
10,874,4137,220,4187,431,0106,558,5846,536,0076,652,8137,001,6717,646,2058,643,5028,654,9118,818,0135,064,9775,540,3785,542,1035,283,4655,188,4265,944,4511,715,8361,604,7071,787,0681,280,6601,251,8841,165,17401,078,175
       Cash And Cash Equivalents 
305,500
0
225,574
305,059
320,711
825,982
339,543
318,190
4,459,852
3,558,420
3,053,203
2,954,144
2,942,353
2,210,849
5,968,797
4,289,872
3,543,820
2,913,716
2,848,680
2,042,502
1,497,484
2,055,504
2,512,732
2,058,719
5,918,915
5,918,9152,058,7192,512,7322,055,5041,497,4842,042,5022,848,6802,913,7163,543,8204,289,8725,968,7972,210,8492,942,3532,954,1443,053,2033,558,4204,459,852318,190339,543825,982320,711305,059225,5740305,500
       Short-term Investments 
-253,935
0
-231,015
648
413
-280,273
125,000
142,000
183,451
375,851
727,472
1,046,159
910,010
1,049,825
757,147
1,661,953
1,554,621
1,431,492
597,634
698,213
745,362
491,098
637,198
924,252
621,983
621,983924,252637,198491,098745,362698,213597,6341,431,4921,554,6211,661,953757,1471,049,825910,0101,046,159727,472375,851183,451142,000125,000-280,273413648-231,0150-253,935
       Net Receivables 
590,550
0
695,477
729,614
733,150
708,927
886,998
960,545
1,033,762
958,697
1,136,247
1,130,995
1,263,495
1,308,615
1,430,082
1,471,174
1,564,871
1,682,324
2,043,942
2,329,674
2,332,252
2,609,538
2,672,504
2,613,817
2,242,026
2,242,0262,613,8172,672,5042,609,5382,332,2522,329,6742,043,9421,682,3241,564,8711,471,1741,430,0821,308,6151,263,4951,130,9951,136,247958,6971,033,762960,545886,998708,927733,150729,614695,4770590,550
       Inventory 
93,267
0
121,801
127,151
120,462
153,249
143,106
161,330
157,397
189,093
231,292
257,317
281,617
318,800
445,341
567,550
680,040
788,649
923,707
1,017,870
1,041,461
1,072,500
1,039,349
342,444
1,013,079
1,013,079342,4441,039,3491,072,5001,041,4611,017,870923,707788,649680,040567,550445,341318,800281,617257,317231,292189,093157,397161,330143,106153,249120,462127,151121,801093,267
       Other Current Assets 
88,859
0
122,323
89,412
105,925
98,909
110,060
133,772
109,988
106,366
135,251
153,487
142,904
176,889
216,646
664,362
1,300,150
830,023
587,707
564,555
919,447
329,943
569,227
687,894
553,075
553,075687,894569,227329,943919,447564,555587,707830,0231,300,150664,362216,646176,889142,904153,487135,251106,366109,988133,772110,06098,909105,92589,412122,323088,859
   > Long-term Assets 
2,840,999
0
3,100,301
3,225,401
3,344,819
3,356,529
3,742,620
3,858,348
3,990,587
4,088,466
4,700,368
4,944,251
6,368,414
7,696,916
8,219,687
8,881,144
9,745,622
11,014,716
11,965,201
13,054,092
13,956,551
14,488,986
14,959,072
15,255,595
15,602,300
15,602,30015,255,59514,959,07214,488,98613,956,55113,054,09211,965,20111,014,7169,745,6228,881,1448,219,6877,696,9166,368,4144,944,2514,700,3684,088,4663,990,5873,858,3483,742,6203,356,5293,344,8193,225,4013,100,30102,840,999
       Property Plant Equipment 
2,094,263
0
2,329,801
2,401,741
2,376,668
2,394,011
2,645,426
2,729,180
2,882,287
2,922,348
3,088,520
3,345,941
3,798,703
4,202,298
4,708,360
5,061,032
5,667,331
6,364,518
6,957,290
7,655,254
8,285,750
8,761,313
9,303,961
9,680,337
9,904,810
9,904,8109,680,3379,303,9618,761,3138,285,7507,655,2546,957,2906,364,5185,667,3315,061,0324,708,3604,202,2983,798,7033,345,9413,088,5202,922,3482,882,2872,729,1802,645,4262,394,0112,376,6682,401,7412,329,80102,094,263
       Goodwill 
133,524
0
135,125
140,228
139,917
137,397
201,313
205,165
203,286
205,402
364,225
358,989
1,166,172
1,172,594
1,804,929
1,813,810
2,096,265
2,363,931
2,535,957
2,562,966
2,687,865
2,687,644
2,814,376
2,763,654
2,780,918
2,780,9182,763,6542,814,3762,687,6442,687,8652,562,9662,535,9572,363,9312,096,2651,813,8101,804,9291,172,5941,166,172358,989364,225205,402203,286205,165201,313137,397139,917140,228135,1250133,524
       Intangible Assets 
302,020
0
298,487
330,300
389,870
390,090
406,922
418,122
420,574
416,634
464,168
460,745
566,076
638,411
654,434
649,751
692,935
748,408
724,385
723,007
802,535
828,790
805,050
215,452
789,057
789,057215,452805,050828,790802,535723,007724,385748,408692,935649,751654,434638,411566,076460,745464,168416,634420,574418,122406,922390,090389,870330,300298,4870302,020
       Long-term Assets Other 
46,364
0
74,369
293,811
379,720
43,746
441,132
448,118
471,221
687,838
1,042,304
1,379,852
1,337,333
2,272,434
1,300,090
2,344,955
2,065,448
2,105,285
1,330,882
1,702,466
1,858,662
1,594,208
1,629,050
262,375
291,215
291,215262,3751,629,0501,594,2081,858,6621,702,4661,330,8822,105,2852,065,4482,344,9551,300,0902,272,4341,337,3331,379,8521,042,304687,838471,221448,118441,13243,746379,720293,81174,369046,364
> Total Liabilities 
1,908,882
0
2,138,519
2,237,292
2,283,560
2,310,379
2,431,071
2,503,299
2,097,020
1,356,007
1,774,897
1,956,455
2,975,053
3,609,823
7,534,435
7,632,127
8,093,818
8,316,165
8,677,751
9,165,742
9,652,690
9,772,959
10,083,179
10,571,073
13,238,666
13,238,66610,571,07310,083,1799,772,9599,652,6909,165,7428,677,7518,316,1658,093,8187,632,1277,534,4353,609,8232,975,0531,956,4551,774,8971,356,0072,097,0202,503,2992,431,0712,310,3792,283,5602,237,2922,138,51901,908,882
   > Total Current Liabilities 
941,019
0
1,207,113
1,235,537
1,255,809
1,281,146
1,436,764
1,457,742
1,269,681
998,747
1,325,159
1,326,170
1,981,789
2,298,653
2,515,522
2,551,891
2,981,997
3,086,492
3,395,331
3,646,401
3,912,433
3,934,762
4,042,671
3,712,925
3,654,476
3,654,4763,712,9254,042,6713,934,7623,912,4333,646,4013,395,3313,086,4922,981,9972,551,8912,515,5222,298,6531,981,7891,326,1701,325,159998,7471,269,6811,457,7421,436,7641,281,1461,255,8091,235,5371,207,1130941,019
       Short-term Debt 
471,741
0
671,425
614,545
539,807
665,247
648,042
697,458
364,804
95,771
101,756
139,321
470,070
481,620
491,147
514,575
577,593
599,704
624,221
637,449
901,747
926,358
726,781
0
0
00726,781926,358901,747637,449624,221599,704577,593514,575491,147481,620470,070139,321101,75695,771364,804697,458648,042665,247539,807614,545671,4250471,741
       Short Long Term Debt 
0
0
0
0
0
497,392
409,289
415,449
213,951
5,226
7,958
42,568
377,265
388,575
389,379
407,454
421,757
413,444
409,029
400,786
662,767
664,082
461,544
534,848
577,071
577,071534,848461,544664,082662,767400,786409,029413,444421,757407,454389,379388,575377,26542,5687,9585,226213,951415,449409,289497,39200000
       Accounts payable 
91,640
0
102,582
115,612
108,220
103,430
122,056
124,020
117,978
154,028
164,164
132,209
191,497
220,329
268,436
283,662
315,534
354,756
466,382
465,095
406,348
428,664
416,502
400,934
412,221
412,221400,934416,502428,664406,348465,095466,382354,756315,534283,662268,436220,329191,497132,209164,164154,028117,978124,020122,056103,430108,220115,612102,582091,640
       Other Current Liabilities 
106,939
0
122,606
150,936
187,156
192,610
238,753
282,008
150,853
90,544
93,797
96,753
1,268,387
1,513,487
1,656,411
1,630,513
13,782
2,132,032
2,304,727
2,543,857
2,604,338
2,579,740
2,899,388
29,260
24,586
24,58629,2602,899,3882,579,7402,604,3382,543,8572,304,7272,132,03213,7821,630,5131,656,4111,513,4871,268,38796,75393,79790,544150,853282,008238,753192,610187,156150,936122,6060106,939
   > Long-term Liabilities 
967,864
0
931,406
1,001,755
1,027,751
1,029,233
994,308
1,045,557
827,339
357,260
449,738
630,285
993,264
1,311,170
5,018,913
5,080,237
5,111,821
5,229,673
5,282,421
5,519,341
5,740,257
5,838,197
6,040,507
6,036,402
9,584,191
9,584,1916,036,4026,040,5075,838,1975,740,2575,519,3415,282,4215,229,6735,111,8215,080,2375,018,9131,311,170993,264630,285449,738357,260827,3391,045,557994,3081,029,2331,027,7511,001,755931,4060967,864
       Long term Debt Total 
0
0
0
0
0
0
864,759
0
674,951
201,843
285,188
412,932
581,419
901,293
4,496,261
4,630,469
4,707,523
4,797,962
4,826,055
5,069,656
5,214,776
5,228,557
5,376,828
5,378,866
0
05,378,8665,376,8285,228,5575,214,7765,069,6564,826,0554,797,9624,707,5234,630,4694,496,261901,293581,419412,932285,188201,843674,9510864,759000000
       Other Liabilities 
0
0
0
0
0
0
129,549
130,748
152,388
155,416
164,551
217,354
411,845
409,878
522,653
449,768
404,298
431,711
456,366
449,684
0
0
663,680
0
0
00663,68000449,684456,366431,711404,298449,768522,653409,878411,845217,354164,551155,416152,388130,748129,549000000
       Deferred Long Term Liability 
0
0
0
0
0
0
232,848
218,059
204,835
191,879
179,940
167,188
234,271
216,689
198,664
188,077
171,601
206,803
242,268
362,837
0
0
479,422
0
0
00479,42200362,837242,268206,803171,601188,077198,664216,689234,271167,188179,940191,879204,835218,059232,848000000
> Total Stockholder Equity
1,997,674
0
2,114,607
2,227,048
2,328,928
2,822,548
2,833,897
2,994,549
7,767,063
7,857,668
8,133,861
8,464,568
8,870,320
9,097,316
9,366,636
9,757,935
10,129,241
10,204,814
10,155,581
10,401,704
10,548,615
10,979,427
11,535,329
11,904,941
12,556,797
12,556,79711,904,94111,535,32910,979,42710,548,61510,401,70410,155,58110,204,81410,129,2419,757,9359,366,6369,097,3168,870,3208,464,5688,133,8617,857,6687,767,0632,994,5492,833,8972,822,5482,328,9282,227,0482,114,60701,997,674
   Common Stock
590,664
0
590,664
590,664
590,664
656,294
656,294
656,294
794,387
794,387
794,387
794,387
794,387
794,387
794,387
794,177
794,177
794,177
1,191,068
1,191,068
1,191,225
1,191,225
1,786,732
1,786,732
0
01,786,7321,786,7321,191,2251,191,2251,191,0681,191,068794,177794,177794,177794,387794,387794,387794,387794,387794,387794,387656,294656,294656,294590,664590,664590,6640590,664
   Retained Earnings 
240,996
0
363,156
471,625
548,265
602,907
622,226
789,283
962,220
1,063,738
1,322,022
1,632,105
1,929,024
2,174,898
2,255,674
2,730,901
3,221,775
3,470,862
3,452,014
3,827,688
4,152,381
4,500,709
4,581,128
10,383,107
5,204,512
5,204,51210,383,1074,581,1284,500,7094,152,3813,827,6883,452,0143,470,8623,221,7752,730,9012,255,6742,174,8981,929,0241,632,1051,322,0221,063,738962,220789,283622,226602,907548,265471,625363,1560240,996
   Capital Surplus 
0
0
0
0
0
0
1,414,709
0
5,872,090
0
5,875,353
0
0
0
0
0
0
0
0
0
0
0
4,676,550
0
0
004,676,550000000000005,875,35305,872,09001,414,709000000
   Treasury Stock00000000-301,825-145,241-81,391-82,085-45,475-72,170-72,170-72,781-72,78100000000
   Other Stockholders Equity 
1,166,014
0
1,722,786
1,164,760
1,855,057
1,563,348
2,315,805
1,548,972
6,893,760
5,999,542
7,028,671
6,038,075
7,292,756
6,128,030
6,316,575
6,232,857
6,113,289
5,939,775
5,512,499
5,382,948
5,205,010
5,287,493
5,167,469
198,554
0
0198,5545,167,4695,287,4935,205,0105,382,9485,512,4995,939,7756,113,2896,232,8576,316,5756,128,0307,292,7566,038,0757,028,6715,999,5426,893,7601,548,9722,315,8051,563,3481,855,0571,164,7601,722,78601,166,014



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue11,537,996
Cost of Revenue-7,413,512
Gross Profit4,124,4844,124,484
 
Operating Income (+$)
Gross Profit4,124,484
Operating Expense-9,704,667
Operating Income1,833,329-5,580,183
 
Operating Expense (+$)
Research Development448,278
Selling General Administrative1,004,911
Selling And Marketing Expenses-
Operating Expense9,704,6671,453,189
 
Net Interest Income (+$)
Interest Income33,543
Interest Expense-182,192
Other Finance Cost-3,609
Net Interest Income-152,258
 
Pretax Income (+$)
Operating Income1,833,329
Net Interest Income-152,258
Other Non-Operating Income Expenses-
Income Before Tax (EBT)1,837,8871,833,329
EBIT - interestExpense = -182,192
1,601,096
1,783,288
Interest Expense182,192
Earnings Before Interest and Taxes (EBIT)-2,020,079
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax1,837,887
Tax Provision-256,106
Net Income From Continuing Ops1,581,7811,581,781
Net Income1,601,096
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-152,258
 

Technical Analysis of Pharmaron
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pharmaron. The general trend of Pharmaron is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pharmaron's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pharmaron Beijing Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 8.62 < 8.62 < 8.65.

The bearish price targets are: .

Tweet this
Pharmaron Beijing Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pharmaron Beijing Co Ltd. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pharmaron Beijing Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pharmaron Beijing Co Ltd. The current macd is -0.40129357.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Pharmaron price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Pharmaron. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Pharmaron price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Pharmaron Beijing Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartPharmaron Beijing Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pharmaron Beijing Co Ltd. The current adx is 14.46.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Pharmaron shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Pharmaron Beijing Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pharmaron Beijing Co Ltd. The current sar is 9.59456225.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Pharmaron Beijing Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pharmaron Beijing Co Ltd. The current rsi is 39.00. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Pharmaron Beijing Co Ltd Daily Relative Strength Index (RSI) ChartPharmaron Beijing Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pharmaron Beijing Co Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Pharmaron price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Pharmaron Beijing Co Ltd Daily Stochastic Oscillator ChartPharmaron Beijing Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pharmaron Beijing Co Ltd. The current cci is -163.33135196.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Pharmaron Beijing Co Ltd Daily Commodity Channel Index (CCI) ChartPharmaron Beijing Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pharmaron Beijing Co Ltd. The current cmo is -25.65474399.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Pharmaron Beijing Co Ltd Daily Chande Momentum Oscillator (CMO) ChartPharmaron Beijing Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pharmaron Beijing Co Ltd. The current willr is -76.92307692.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Pharmaron is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Pharmaron Beijing Co Ltd Daily Williams %R ChartPharmaron Beijing Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Pharmaron Beijing Co Ltd.

Pharmaron Beijing Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pharmaron Beijing Co Ltd. The current atr is 0.5467794.

Pharmaron Beijing Co Ltd Daily Average True Range (ATR) ChartPharmaron Beijing Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pharmaron Beijing Co Ltd. The current obv is -118,656,737.

Pharmaron Beijing Co Ltd Daily On-Balance Volume (OBV) ChartPharmaron Beijing Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pharmaron Beijing Co Ltd. The current mfi is 45.10.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Pharmaron Beijing Co Ltd Daily Money Flow Index (MFI) ChartPharmaron Beijing Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pharmaron Beijing Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-19MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-19BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Pharmaron Beijing Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pharmaron Beijing Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.000
Ma 20Greater thanMa 509.312
Ma 50Greater thanMa 1009.844
Ma 100Greater thanMa 20012.194
OpenGreater thanClose8.390
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Pharmaron with someone you think should read this too:
  • Are you bullish or bearish on Pharmaron? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pharmaron? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pharmaron Beijing Co Ltd

I send you an email if I find something interesting about Pharmaron Beijing Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Pharmaron Beijing Co Ltd.

Receive notifications about Pharmaron Beijing Co Ltd in your mailbox!